Αρχική World News Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted... World News Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping Από Ogkologos - 11 Νοεμβρίου, 2024 898 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ 7 Φεβρουαρίου, 2019 September 11, 2001 – Strength is Not Always Unyielding 11 Σεπτεμβρίου, 2021 FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma 14 Αυγούστου, 2020 Pink Van Makes the Rounds Throughout Rural New Zealand to Offer... 24 Φεβρουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Searching for novel connections in cancer metabolism 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients... Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in...